Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 20Active not recruiting 6Terminated 4Unknown 3Recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Squamous Cell Carcinoma of Head and Neck 14Head and Neck Neoplasms 12Lung Neoplasms 10Uterine Cervical Neoplasms 9Neoplasms 9Cholangiocarcinoma 5Carcinoma, Squamous Cell 5Carcinoma 5Mesothelioma, Malignant 4Carcinoma, Hepatocellular 4Tongue Neoplasms 3Small Cell Lung Carcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Mouth Neoplasms 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Breast Neoplasms 3Biliary Tract Neoplasms 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Neoplasms 2Mesothelioma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2

Interventions

Nivolumab 17Ipilimumab 14pembrolizumab 11Cyclophosphamide 8trametinib 7dabrafenib 6Interleukin-2 6aldesleukin 5Vemurafenib 5Radiotherapy 5sargramostim 4130-nm albumin-bound paclitaxel 4fludarabine 3encorafenib 3binimetinib 3Specimen Handling 3Radiosurgery 3Melphalan 3Granulocyte-Macrophage Colony-Stimulating Factor 3fludarabine phosphate 2Magnetic Resonance Spectroscopy 2Introns 2Infliximab 2Celecoxib 2CTLA-4 Antigen 2Biopsy 2Bevacizumab 2Albumin-Bound Paclitaxel 2yeast-CEA vaccine 1vitespin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Melanoma × Cisplatin × Clear all
NCT03167177 2025-02-21

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡